Based on the scientists, it might be worthwhile to prioritize these medication for future repurposing analysis.
Based on a long-term examine lately printed within the open-access journal BMJ Open Diabetes Analysis & Care, utilizing the diabetes drug often known as glitazones is related to a 22% decrease threat of dementia. Glitazones are sometimes often known as thiazolidinediones or TZDs for brief and are an older class of sort 2 diabetes medication.
Based on the researchers, these medication might successfully stop dementia in high-risk people with delicate to reasonable sort 2 diabetes, and it could now be worthwhile to present them precedence in future medical trials to find out whether or not they are often repurposed.
Researchers have begun to research whether or not diabetes medication may probably assist stop or treatment dementia since sort 2 diabetes and dementia share a number of physiological patterns. Nonetheless, the outcomes have been inconsistent so far.
The researchers in contrast the incidence of dementia in older adults with sort 2 diabetes who had been receiving both sulfonylurea or thiazolidinedione (TZD) with these receiving metformin alone as a way to shed additional gentle on this.
They used information from 559,106 people with sort 2 diabetes who had been recognized within the nationwide Veteran Affairs (VA) Well being System between January 2000 and December 2019.
Solely older sufferers (aged at the very least 60) and given a primary prescription of metformin, a sulfonylurea (tolbutamide, glimepiride, glipizide, or glyburide), or a TZD (rosiglitazone or pioglitazone) between January 2001 and December 2017 had been included (559,106) within the examine. Their well being was tracked for a median of practically 8 years.
After at the very least 1 12 months of drug remedy, using a TZD alone was related to a 22% decrease threat of dementia from any trigger, in contrast with using metformin alone.
Particularly, it was related to an 11% decrease threat of
Further in-depth analysis indicated that those younger than 75 benefited more from a TZD than older patients, highlighting the importance of early prevention for dementia, note the researchers. And these drugs also seemed to be more protective in overweight or obese patients.
This is an observational study, so definitive conclusions can’t be drawn about cause and effect. And the researchers acknowledge that certain potentially influential information wasn’t available, including kidney function and genetic factors, and that study participants were predominantly male and White.
But they suggest that future studies for repurposing diabetes drugs for dementia prevention might want to consider prioritizing TZDs, based on their findings.
And they conclude: “These findings may help inform medication selection for [older] sufferers with [type 2 diabetes] at excessive threat of dementia.”
Reference: “Use of oral diabetes medicines and the danger of incident dementia in US veterans aged ≥60 years with sort 2 diabetes” by Xin Tang, Roberta Diaz Brinton, Zhao Chen, Leslie V. Farland, Yann Klimentidis, Raymond Migrino, Peter Reaven, Kathleen Rodgers and Jin J Zhou, 11 October 2022, BMJ Open Diabetes Analysis & Care.
The examine was funded by the Nationwide Human Genome Analysis Institute, the Nationwide Science Basis, the Nationwide Institute of Diabetes and Digestive and Kidney Illness, and the Nationwide Coronary heart, Lung, and Blood Institute.